Vertex Pharmaceuticals Incorporated (VRTX)

Healthcare | Biotechnology
Latest reporting period: 2025-03-31

Latest Quarter

2025-03-31

Revenue

$2.8B

Net Income

$646M

Operating Margin

22.7%

Free Cash Flow

-$790M

Debt / Assets

27.2%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Vertex Pharmaceuticals Incorporated (VRTX).
Income Statement (Quarterly) 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Revenue 2,770,200,000 2,912,000,000 2,771,900,000 2,645,600,000
Cost of Revenue 363,000,000 423,400,000 392,600,000 371,900,000
Gross Profit 2,407,200,000 2,488,600,000 2,379,300,000 2,273,700,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 396,400,000 377,600,000 371,800,000 372,200,000
Operating Expenses 1,777,100,000 1,376,300,000 1,263,000,000 5,788,400,000
Operating Income 630,100,000 1,026,000,000 1,116,300,000 -3,514,700,000
Interest Expense 3,000,000 2,800,000 7,500,000 9,900,000
Income Before Tax 730,400,000 1,136,500,000 1,224,100,000 -3,391,200,000
Income Tax Expense 84,100,000 223,500,000 178,700,000 202,400,000
Net Income 646,300,000 913,000,000 1,045,400,000 -3,593,600,000
Per Share
EPS 2.52 3.55 4.05 -13.92
EPS Diluted 0.00 0.00 0.00 0.00